Tom Smart has a distinguished 25-year career as a biotech executive, demonstrating dynamic leadership in roles such as CEO, CBO, SVP, and Board Member. With a proven track record of success, he has spearheaded the development of multiple promising product pipelines and candidates, culminating in the FDA and EU approval of the immuno-oncology PD-1 checkpoint inhibitor, Jemperli (dostarlimab/GSK). Mr. Smart is an expert in orchestrating pivotal transitions for biopharma companies, guiding them from research to clinical stage, and facilitating their evolution from privately held to publicly traded entities. Mr. Smart’s adeptness in securing a diverse range of transactions, including private financings, initial public offerings, corporate partnerships, and mergers and acquisitions, underscores his strategic acumen and breadth of industry experience.